Aptamer Group and AstraZeneca have entered a collaboration agreement to evaluate Aptamer’s Optimer fibrotic liver delivery vehicles for the targeted delivery of small interfering RNA (siRNA). Following the encouraging results achieved to-date with Aptamer’s fibrotic liver delivery vehicles, the next phase of the research will explore the potential of the non-viral delivery vehicle and its […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
